Abstract
Metabolic syndrome (MetS), a cluster of dyslipidaemia, central obesity, hypertension and/or insulin resistance, is associated with increased cardiovascular disease (CVD) type 2 diabetes risk. Different diagnostic criteria for MetS have been proposed but in 2009 a joint statement by several scientific societies was released.
Apart from the diagnostic criteria, MetS has also been associated with other risk factors including waist to hip ratio, high density lipoprotein dysfunction, small dense low density lipoprotein, postprandial hypertriglyceridaemia, lipoprotein (a), uric acid, liver function tests, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, renal dysfunction, nephrolithiasis, polycystic ovary syndrome, obstructive sleep apnea.
We discuss the extensive list of MetS-associated factors that may influence vascular risk. Furthermore, we discuss the impact of frequently prescribed drugs (e.g. hypolipidaemic agents) on these variables. These effects may need to be taken into consideration when treating MetS patients.
Keywords: Arterial stiffness, cytokines, diagnostic criteria, lipids, metabolic syndrome, platelets, renal dysfunction, uric acid.
Current Vascular Pharmacology
Title:Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Volume: 12 Issue: 4
Author(s): Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Arterial stiffness, cytokines, diagnostic criteria, lipids, metabolic syndrome, platelets, renal dysfunction, uric acid.
Abstract: Metabolic syndrome (MetS), a cluster of dyslipidaemia, central obesity, hypertension and/or insulin resistance, is associated with increased cardiovascular disease (CVD) type 2 diabetes risk. Different diagnostic criteria for MetS have been proposed but in 2009 a joint statement by several scientific societies was released.
Apart from the diagnostic criteria, MetS has also been associated with other risk factors including waist to hip ratio, high density lipoprotein dysfunction, small dense low density lipoprotein, postprandial hypertriglyceridaemia, lipoprotein (a), uric acid, liver function tests, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, renal dysfunction, nephrolithiasis, polycystic ovary syndrome, obstructive sleep apnea.
We discuss the extensive list of MetS-associated factors that may influence vascular risk. Furthermore, we discuss the impact of frequently prescribed drugs (e.g. hypolipidaemic agents) on these variables. These effects may need to be taken into consideration when treating MetS patients.
Export Options
About this article
Cite this article as:
Katsiki Niki, Athyros G. Vasilios, Karagiannis Asterios and Mikhailidis P. Dimitri, Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/15701611113119990131
DOI https://dx.doi.org/10.2174/15701611113119990131 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Staurosporine-Activated Volume-Sensitive Outwardly Rectifying Cl- Channel by PI3K/Akt in Cardiomyocytes
Current Pharmaceutical Design Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Inhibition of RAGE Axis Signaling: A Pharmacological Challenge
Current Drug Targets Thermal Taste and Anti-Aspiration Drugs: A Novel Drug Discovery Against Pneumonia
Current Pharmaceutical Design Therapeutic Targets to Raise HDL in Patients at Risk or with Coronary Artery Disease
Current Vascular Pharmacology Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease
Current Pharmaceutical Design The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Post Cardiovascular Surgery Atrial Fibrillation. Biomarkers Determining Prognosis
Current Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Anti-Angiogenic Therapy in Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets New Target Molecules in the Drug Control of Blood Pressure and Circulation
Current Drug Targets - Cardiovascular & Hematological Disorders Vascular Effects of Ambient Pollutant Particles and Metals
Current Vascular Pharmacology Transforming Growth Factor-β (TGF-β ) and its Role in the Pathogenesis of Systemic Sclerosis: A Novel Target for Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Nitric Oxide, Malnutrition and Chronic Renal Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials